Galapagos NV (NASDAQ:GLPG) had its price objective raised by investment analysts at Stifel Nicolaus from $101.00 to $120.00 in a report released on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price objective would suggest a potential upside of 15.99% from the company’s current price.

Several other research firms have also weighed in on GLPG. BidaskClub lowered shares of Galapagos NV from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Nomura lowered their target price on shares of Galapagos NV from $108.00 to $121.00 and set a “buy” rating for the company in a research note on Thursday, June 22nd. Instinet reiterated a “buy” rating and set a $108.00 target price (down previously from $121.00) on shares of Galapagos NV in a research note on Thursday, June 22nd. Morgan Stanley reiterated an “overweight” rating and set a $92.00 target price on shares of Galapagos NV in a research note on Thursday, August 10th. Finally, Cowen and Company reiterated a “buy” rating on shares of Galapagos NV in a research note on Thursday, August 10th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $104.67.

Galapagos NV (NASDAQ GLPG) opened at 103.46 on Friday. The firm’s 50-day moving average is $101.59 and its 200 day moving average is $84.97. Galapagos NV has a 12 month low of $57.16 and a 12 month high of $103.54. The stock’s market capitalization is $5.26 billion.

WARNING: This report was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/15/galapagos-nv-glpg-price-target-raised-to-120-00.html.

Several institutional investors have recently added to or reduced their stakes in GLPG. Geduld E E bought a new position in shares of Galapagos NV during the fourth quarter worth about $692,000. Alps Advisors Inc. bought a new position in shares of Galapagos NV during the fourth quarter worth about $3,232,000. Morgan Stanley grew its position in shares of Galapagos NV by 38.0% during the fourth quarter. Morgan Stanley now owns 112,640 shares of the biotechnology company’s stock worth $7,083,000 after acquiring an additional 31,019 shares during the last quarter. Driehaus Capital Management LLC bought a new position in shares of Galapagos NV during the fourth quarter worth about $1,691,000. Finally, DAFNA Capital Management LLC grew its position in shares of Galapagos NV by 1,655.4% during the fourth quarter. DAFNA Capital Management LLC now owns 30,000 shares of the biotechnology company’s stock worth $1,886,000 after acquiring an additional 28,291 shares during the last quarter. Institutional investors and hedge funds own 23.63% of the company’s stock.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.